Cannabinoid withdrawal in mice: Inverse agonist vs neutral antagonist

Psychopharmacology

Volumn 232, Issue 15, 2015, Pages 2751-2761

  Tai, Sherrica ^a,b   Nikas, Spyros P ^a   Shukla, Vidyanand G ^a   Vemuri, Kiran ^a   Makriyannis, Alexandros ^a   Järbe, Torbjörn U C ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

AM2389; AM4113; AM6545; Antagonist; Cannabinoid; Dependence; Mice; THC; Tolerance; Withdrawal

Indexed keywords

AM 2389; AM 4113; AM 6545; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; RIMONABANT; UNCLASSIFIED DRUG; AM4113; AM6545; MORPHOLINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CATALEPSY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; INVERSE AGONISM; LATENT PERIOD; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RECEPTOR BLOCKING; TEMPERATURE MEASUREMENT; WITHDRAWAL SYNDROME; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY TEMPERATURE; DISEASE MODEL; DRUG EFFECTS; DRUG TOLERANCE; MOTOR ACTIVITY;

ANIMALS; BODY TEMPERATURE; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DRONABINOL; DRUG TOLERANCE; MALE; MICE; MORPHOLINES; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84937726941     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-3907-0     Document Type: Article

References (44)

1. Aceto MD, Scates SM, Lowe JA, Martin BR (1996) Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295
2. Aceto MD, Scates SM, Martin BB (2001) Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 416:75-81
3. Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311-1322
4. Carlini EA (1968) Tolerance to chronic administration of Cannabis sativa (marihuana) in rats. Pharmacology 1:135-142
5. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, Sharkey KA (2007) A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193
6. Chaperon F, Thiebot MH (1999) Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243-281
7. Chopda GR, Vemuri VK, Sharma R, Thakur GA, Makriyannis A, Paronis CA (2013) Diuretic effects of cannabinoid agonists in mice. Eur J Pharmacol 721:64-69
8. Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150-1156
9. Coughenour LL, McLean JR, Parker RB (1977) A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav 6:351-353
10. Fan F, Compton DR, Ward S, Melvin L, Martin BR (1994) Development of cross-tolerance between delta-9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271:1383-1390
11. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88
12. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW (2002) Comparison of smoked marijuana and oral delta (9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 164:407-415
13. Huang P, Liu-Chen LY, Unterwald EM, Cowan A (2009) Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. Neurosci Lett 465:66-70
14. Huang P, Liu-Chen LY, Kirby LG (2010) Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neurosci Lett 475:165-168
15. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567-1577
16. Järbe TUC (1978) Delta-9-tetrahydrocannabinol: tolerance after noncontingent exposure in rats. Arch Int Pharmacodyn Ther 231:49-56
17. Järbe TUC, Swedberg MD, Mechoulam R (1981) A repeated test procedure to assess onset and duration of the cue properties of (-) delta 9-THC, (-) delta 8-THC-DMH and (+) delta 8-THC. Psychopharmacology (Berl) 75:152-157
18. Järbe TUC, Hiltunen AJ, Lander N, Mechoulam R (1986) Cannabimimetic activity (delta 1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav 25:393-399
19. Järbe TUC, LeMay BJ, Vemuri VK, Vadivel SK, Zvonok A, Makriyannis A (2011) Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) 216:355-365
20. Järbe TUC, Tai S, Lemay BJ, Nikas SP, Shukla VG, Zvonok A, Makriyannis A (2012) AM2389, a high-affinity, in vivo potent CB (1)-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl) 220:417-426
21. Jones RT, Benowitz N (1976) The 30-day trip. Clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S (eds) In pharmacology of marijuana. Academic, New York
22. Jones RT, Benowitz N, Bachman J (1976) Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 282:221-239
23. Jones RT, Benowitz NL, Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21:143S-152S
24. Kishimoto Y, Kano M (2006) Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. J Neurosci 26:8829-8837
25. Lichtman AH, Martin BR (2005) Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168:691-717
26. Lichtman AH, Fisher J, Martin BR (2001) Precipitated cannabinoid withdrawal is reversed by delta-9-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 69:181-188
27. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002) Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302:73-79
28. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448
29. Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326-3331
30. Mato S, Pazos A, Valdizan EM (2002) Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur J Pharmacol 443:43-46
31. McMahon LR, Koek W (2007) Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol 569:70-76
32. Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, Adan RA (2013) Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 18:1294-1301
33. National Institute of Health (1996) Principles of animal laboratory care. National Academy, Washington, DC
34. Nikas SP, Alapafuja SO, Papanastasiou I, Paronis CA, Shukla VG, Papahatjis DP, Bowman AL, Halikhedkar A, Han X, Makriyannis A (2010) Novel 1′,1′-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem 53:6996-7010
35. Oliva JM, Ortiz S, Palomo T, Manzanares J (2003) Behavioural and gene transcription alterations induced by spontaneous cannabinoid withdrawal in mice. J Neurochem 85:94-104
36. Rawls SM, Cabassa J, Geller EB, Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301:963-968
37. Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119
38. Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91:383-388
39. Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, Makriyannis A, Parker LA, Salamone JD (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946-955
40. Tai S, Fantegrossi W (2014) Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential. Curr Addict Rep 1-8
41. Tai S, Järbe TUC, Nikas SP, Makriyannis A (2011) Characterization of a CB1 receptor agonist (AM2389) with a long duration of effect to facilitate the study of CB1 dependence/withdrawal. International Cannabinoid Research Society (ICRS), Research Triangle Park, NC
42. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966
43. Thakur GA, Nikas SP, Makriyannis A (2005) CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5:631-640
44. Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH (2006) SR 141716 (rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav 85:105-113